Last reviewed · How we verify
Bismuth potassium citrate placebo capsules
This is a placebo formulation containing bismuth potassium citrate with no active therapeutic mechanism.
This is a placebo formulation containing bismuth potassium citrate with no active therapeutic mechanism. Used for Control arm in Phase 3 clinical trial (specific indication unknown).
At a glance
| Generic name | Bismuth potassium citrate placebo capsules |
|---|---|
| Also known as | Bismuth placebo, Bismuth, Bismuth Potassium Citrate |
| Sponsor | TenNor Therapeutics (Suzhou) Limited |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Bismuth potassium citrate is a known anti-ulcer agent that can reduce gastric acid and provide cytoprotection, but this product is explicitly a placebo capsule used as a control in clinical trials. It contains no active drug and is designed to be indistinguishable from an active comparator for blinding purposes in Phase 3 studies.
Approved indications
- Control arm in Phase 3 clinical trial (specific indication unknown)
Common side effects
Key clinical trials
- Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection (PHASE3)
- Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori (PHASE3)
- Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection (PHASE3)
- Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: